Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma

Glenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, Monique Henket, Renaud Louis, Florence Schleich, Fabrice Bureau, Christophe J. Desmet
European Respiratory Journal 2022 59: 2100935; DOI: 10.1183/13993003.00935-2021
Glenn Van Hulst
1Laboratory of Cellular and Molecular Immunology, GIGA Institute and Faculty of Veterinary Medicine, Liege University, Liege, Belgium
4Equal contributors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Glenn Van Hulst
Joseph Jorssen
1Laboratory of Cellular and Molecular Immunology, GIGA Institute and Faculty of Veterinary Medicine, Liege University, Liege, Belgium
4Equal contributors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Jacobs
1Laboratory of Cellular and Molecular Immunology, GIGA Institute and Faculty of Veterinary Medicine, Liege University, Liege, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monique Henket
2Laboratory of Pneumology, GIGA Institute, Faculty of Medicine and University Hospital Center, Liege University, Liege, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renaud Louis
2Laboratory of Pneumology, GIGA Institute, Faculty of Medicine and University Hospital Center, Liege University, Liege, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florence Schleich
2Laboratory of Pneumology, GIGA Institute, Faculty of Medicine and University Hospital Center, Liege University, Liege, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrice Bureau
1Laboratory of Cellular and Molecular Immunology, GIGA Institute and Faculty of Veterinary Medicine, Liege University, Liege, Belgium
3Walloon Excellence in Life Sciences and Biotechnology (Welbio), Wavres, Belgium
4Equal contributors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe J. Desmet
1Laboratory of Cellular and Molecular Immunology, GIGA Institute and Faculty of Veterinary Medicine, Liege University, Liege, Belgium
4Equal contributors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christophe J. Desmet
  • For correspondence: christophe.desmet@uliege.be
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Neutralising antibodies against the cytokine interleukin (IL)5 have become widely used for the control of severe eosinophilic asthma. Remarkably, patients receiving neutralising anti-IL5 biological therapies retain a very stable population of residual blood eosinophils. Whether these residual eosinophils are endowed with particular biological activity has not yet been studied, but is of importance in predicting potential long-term effects of IL5 neutralisation in patients. To tackle the effect of IL5 depletion on residual eosinophils, we used a comparative RNA-sequencing approach and compared the gene expression programme of eosinophils arising in IL5-depleted or IL5-replete human or murine hosts, at steady-state in vivo and following in vitro stimulation with the eosinophil-activating alarmin IL33. We compared blood eosinophils from patients with severe allergic eosinophilic asthma treated with anti-IL5 mepolizumab therapy to those of healthy controls and matched asthma patients receiving anti-IgE omalizumab therapy. We made similar comparisons on bone marrow eosinophils from mice genetically deficient or not for IL5. We report that restriction of IL5 availability did not elicit any detectable transcriptional response in steady-state residual eosinophils in mepolizumab-treated patients or IL5-deficient mice, and influenced only a handful of genes in their response to IL33. Together, these results support the notion that treatment with IL5 neutralising antibodies spares a pool of circulating residual eosinophils largely resembling those of healthy individuals.

Abstract

Asthma patients receiving anti-IL5 therapies retain residual blood eosinophils, of which potential alterations remain unknown. This study shows that these residual eosinophils harbour largely unaltered quiescent and activated gene expression programmes. https://bit.ly/37od6QN

Footnotes

  • Conflict of interest: G. Van Hulst has nothing to disclose.

  • Conflict of interest: J. Jorssen reports PhD student scholarship from Fonds de la Recherche scientifique (FRS)-FNRS (Belgium).

  • Conflict of interest: N. Jacobs reports consulting fees and lecture fees from GSK, outside the submitted work.

  • Conflict of interest: M. Henket has nothing to disclose.

  • Conflict of interest: R. Louis reports grants from GSK, AZ, Novartis, Chiesi and Teva; royalties from patent AU2016328384, CA2997506, EP 3337393, US2020345266; consulting fees and lecture payments from GSK, AZ, Novartis, Sanofi and Chiesi, outside the submitted work.

  • Conflict of interest: F. Schleich reports grants from GSK, AstraZeneca, Teva, Chiesi and Novartis; consulting fees from GSK, AstraZeneca, Amgen, Chiesi and Novartis; lecture payments from GSK, AstraZeneca, Teva, Chiesi and Novartis, outside the submitted work.

  • Conflict of interest: F. Bureau has nothing to disclose.

  • Conflict of interest: C.J. Desmet reports salary from Fonds de la Reherche Scientifique – FNRS (Belgium), during the submitted work; consulting fees from AstraZeneca; lecture fees for presentation at several scientific symposia from GSK, outside the submitted work.

  • Support statement: This work was supported by the Fonds Wetenschappelijk Onderzoek – Vlaanderen (FWO) and the Fonds de la Recherche Scientifique (FRS) – FNRS (Belgium) under EOS project number 30565447 (U-HEAD), by a research project grant (T.0052.18 REGEOS) of the FRS-FNRS, by the Leon Fredericq Foundation (Liege University), and by Liege University. J. Jorssen is a doctoral research fellow, and C.J. Desmet is a research associate of the FRS-FNRS. Funding sources were not involved in the research. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received March 30, 2021.
  • Accepted July 30, 2021.
  • Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 59 Issue 3 Table of Contents
European Respiratory Journal: 59 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma
Glenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, Monique Henket, Renaud Louis, Florence Schleich, Fabrice Bureau, Christophe J. Desmet
European Respiratory Journal Mar 2022, 59 (3) 2100935; DOI: 10.1183/13993003.00935-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma
Glenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, Monique Henket, Renaud Louis, Florence Schleich, Fabrice Bureau, Christophe J. Desmet
European Respiratory Journal Mar 2022, 59 (3) 2100935; DOI: 10.1183/13993003.00935-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Material and methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Research Articles

  • Acid reflux and the airway epithelium in severe asthma
  • Association of lung function and pulmonary vasculature volume with cardiorespiratory fitness
  • Eosinophil airway wall location is critical in airway hyperresponsiveness
Show more Original Research Articles

Asthma

  • Acid reflux and the airway epithelium in severe asthma
  • Eosinophil airway wall location is critical in airway hyperresponsiveness
  • Asthma phenotype/severity determines bronchial epithelial immune response
Show more Asthma

2

  • Asthma and COVID-19 risk: systematic review and meta-analysis
  • Obesity and pulmonary deposition of particulate matter in children with asthma
Show more 2

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society